Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

Related Articles by Review for PubMed (Select 16030277)

1.
2.

Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.

Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM Jr, Ridker PM, Grundy SM, Kastelein JJ.

J Am Coll Cardiol. 2014 Aug 5;64(5):485-94. doi: 10.1016/j.jacc.2014.02.615. Review.

4.
6.

Critical appraisal of inflammatory markers in cardiovascular risk stratification.

Krintus M, Kozinski M, Kubica J, Sypniewska G.

Crit Rev Clin Lab Sci. 2014 Oct;51(5):263-79. doi: 10.3109/10408363.2014.913549. Epub 2014 Jun 11. Review.

PMID:
24918900
7.

Effects of long-term, self-monitored exercise on the serum lipoprotein and apolipoprotein profile in middle-aged men.

Marti B, Suter E, Riesen WF, Tschopp A, Wanner HU, Gutzwiller F.

Atherosclerosis. 1990 Feb;81(1):19-31. Review.

PMID:
2407251
8.

Cholesterol, lipoproteins, high-sensitivity c-reactive protein, and other risk factors for atherosclerosis.

Rudolf J, Lewandrowski KB.

Clin Lab Med. 2014 Mar;34(1):113-27, vii. doi: 10.1016/j.cll.2013.11.003. Epub 2014 Jan 14. Review.

PMID:
24507791
9.

The role of advanced lipid testing in the prediction of cardiovascular disease.

Chandra A, Rohatgi A.

Curr Atheroscler Rep. 2014 Mar;16(3):394. doi: 10.1007/s11883-013-0394-9. Review.

10.

HDL and cholesterol handling in the brain.

Vitali C, Wellington CL, Calabresi L.

Cardiovasc Res. 2014 Aug 1;103(3):405-13. doi: 10.1093/cvr/cvu148. Epub 2014 Jun 6. Review.

PMID:
24907980
11.

New risk markers for cardiovascular prevention.

De Backer GG.

Curr Atheroscler Rep. 2014 Aug;16(8):427. doi: 10.1007/s11883-014-0427-z. Review.

PMID:
24881768
12.

Role of C reactive protein (CRP) in leptin resistance.

Hribal ML, Fiorentino TV, Sesti G.

Curr Pharm Des. 2014;20(4):609-15. Review.

13.

Old and new cardiovascular risk factors: from unresolved issues to new opportunities.

Maas R, Böger RH.

Atheroscler Suppl. 2003 Dec;4(4):5-17. Review.

PMID:
14664897
14.

Age as a modifiable risk factor for cardiovascular disease.

Sniderman AD, Furberg CD.

Lancet. 2008 May 3;371(9623):1547-9. doi: 10.1016/S0140-6736(08)60313-X. Epub 2008 Mar 5. Review. No abstract available.

PMID:
18321568
15.

Novel methodologies for biomarker discovery in atherosclerosis.

Hoefer IE, Steffens S, Ala-Korpela M, Bäck M, Badimon L, Bochaton-Piallat ML, Boulanger CM, Caligiuri G, Dimmeler S, Egido J, Evans PC, Guzik T, Kwak BR, Landmesser U, Mayr M, Monaco C, Pasterkamp G, Tuñón J, Weber C; ESC Working Group Atherosclerosis and Vascular Biology.

Eur Heart J. 2015 Jun 5. pii: ehv236. [Epub ahead of print] Review.

PMID:
26049157
16.

Emerging risk biomarkers in cardiovascular diseases and disorders.

Upadhyay RK.

J Lipids. 2015;2015:971453. doi: 10.1155/2015/971453. Epub 2015 Apr 8. Review.

17.

Potential biomarkers in psychiatry: focus on the cholesterol system.

Woods AG, Sokolowska I, Taurines R, Gerlach M, Dudley E, Thome J, Darie CC.

J Cell Mol Med. 2012 Jun;16(6):1184-95. doi: 10.1111/j.1582-4934.2012.01543.x. Review.

18.

Mass Spectrometry-Based Proteomic Study Makes High-Density Lipoprotein a Biomarker for Atherosclerotic Vascular Disease.

Chang CT, Yang CY, Tsai FJ, Lin SY, Chen CJ.

Biomed Res Int. 2015;2015:164846. doi: 10.1155/2015/164846. Epub 2015 May 18. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk